Search results
Results from the WOW.Com Content Network
Acquired generalized lipodystrophy (AGL), also known as Lawrence syndrome [1] and Lawrence–Seip syndrome, [1] is a rare skin condition that appears during childhood or adolescence, characterized by fat loss affecting large areas of the body, particularly the face, arms, and legs.
A more specific term, lipoatrophy (from Greek lipo 'fat' and dystrophy 'abnormal or degenerative condition'), is used when describing the loss of fat from one area (usually the face). This condition is also characterized by a lack of circulating leptin which may lead to osteosclerosis .
The absence of adipose tissue where they normally occur causes the body to store fat in the remaining areas. [7] Common cardiovascular problems related to this syndrome are cardiac hypertrophy and arterial hypertension (high blood pressure). [8] This disorder can also cause metabolic syndrome.
Marfanoid–progeroid–lipodystrophy syndrome (MPL), also known as Marfan lipodystrophy syndrome (MFLS) or progeroid fibrillinopathy, is an extremely rare medical condition which manifests as a variety of symptoms including those usually associated with Marfan syndrome, an appearance resembling that seen in neonatal progeroid syndrome (NPS; also known as Wiedemann–Rautenstrauch syndrome ...
FPL also refers to a rare metabolic condition in which there is a loss of subcutaneous fat in the arms, legs and lower torso. The upper section of the body, face, neck, shoulders, back and trunk carry an excess amount of fat. As the body is unable to store fat correctly this leads to fat around all the vital organs and in the blood (triglycerides).
Melasma (a skin condition that involves patches of dark, discolored skin) Tinnitus (ringing in the ears) Lipoatrophy (loss of fat tissue in specific areas of the body)
️Ease the aches: Depending on your body’s specific reaction to the disease, your doctor may recommend a variety of medications to help you manage your symptoms, including NSAIDs (to treat pain ...
Lipoatrophy is the term describing the localized loss of fat tissue. This may occur as a result of subcutaneous injections of insulin in the treatment of diabetes , from the use of human growth hormone or from subcutaneous injections of copaxone used for the treatment of multiple sclerosis .